In addition, ongoing clinical studies included the application of MBG453 in MRD-positive patients after allo-HSCT (NCT04623216) and in combination with a PD-1 inhibitor (NCT0306664), TP53-MDM2 inhibitor (NCT03940352), or Bcl-2 inhibitors plus HMAs (NCT04812548, NCT04150029) for efficacy and safety in MDS and AML. This evidence concerns the gene MDM2 and acute myeloid leukemia.